Cross Staff Investments’s MIRA Pharmaceuticals MIRA Stock Holding History

Cross Staff Investments’s Portfolio MIRA Stock Details MIRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$340K	Hold	359,401	–	–	0.19%	107
2026 Q1	$385K	Hold	359,401	–	–	0.19%	92
2025 Q4	$543K	Hold	359,401	–	–	0.3%	77
2025 Q3	$489K	Hold	359,401	–	–	0.34%	79
2025 Q2	$435K	Sell	359,401 -4,000	-1%	-$4.62K	0.32%	85
2025 Q1	$356K	Sell	363,401 -2,500	-0.7%	-$2.85K	0.27%	93
2024 Q4	$417K	Hold	365,901	–	–	0.29%	84
2024 Q3	$476K	Sell	365,901 -17,500	-5%	-$27.9K	0.37%	75
2024 Q2	$244K	Hold	383,401	–	–	0.2%	105
2024 Q1	$422K	Buy	+383,401	New	+$416K	0.36%	78

Other funds holding MIRA

FAB

First American Bank Dundee, Illinois $1.79B AUM 30.35% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

CSP

Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Cross Staff Investments's MIRA Position: Q2 2026 in Review

Cross Staff Investments held its MIRA Pharmaceuticals (MIRA) position steady in Q2 2026 at 359,401 shares worth $340K. The position accounts for 0.19% of the portfolio, ranked #107.

Cross Staff Investments first reported a position in MIRA in Q1 2024 and has held it in 10 quarters since. The position peaked at $543K in Q4 2025. 5 funds tracked by Wall St. Rank hold MIRA as of Q2 2026.

Cross Staff Investments held 359,401 shares of MIRA Pharmaceuticals worth $340K as of Q2 2026.
Cross Staff Investments left its MIRA Pharmaceuticals share count unchanged in Q2 2026.
MIRA Pharmaceuticals made up 0.19% of Cross Staff Investments's portfolio in Q2 2026, its #107 holding.
Cross Staff Investments first reported a position in MIRA Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Cross Staff Investments's MIRA Pharmaceuticals position peaked at $543K in Q4 2025.
5 funds tracked by Wall St. Rank held MIRA Pharmaceuticals as of Q2 2026.

Based on Cross Staff Investments's 13F filing for Q2 2026, filed 22 Jul 2026.